ElsaLys Biotech is a frontrunner in therapeutic monoclonal antibody development securing €2.1m in its inaugural financing round. Established in 2013, the Lyon & Illkirch Graffenstaden-France-based company specializes in the development of therapeutic monoclonal antibodies within the Biotechnology, Health Care, Health and Wellness industries. The company's initial round of funding, amounting to €2.1m, was secured through a Series A investment on 17 May 2013. This investment was led by Sofimac Investment Managers and Transgene.
ElsaLys Biotech
A frontrunner in therapeutic monoclonal antibody development secures €2.1m in its inaugural financing round.
Founded 2013
Series A
Total: $2.10M
Biotechnology, Health Care +1
General Information
Company Name
ElsaLys Biotech
Founded Year
2013
Industries
Biotechnology, Health Care, Health and Wellness
Funding Stage
Series A
BounceWatch is an independent company data service, not affiliated with ElsaLys Biotech. To contact ElsaLys Biotech, visit elsalysbiotech.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does ElsaLys Biotech compare?
A PDF of ElsaLys Biotech and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting ElsaLys Biotech soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
Biotechnology
About ElsaLys Biotech
Business keywords: Therapeutic monoclonal antibodies, Biotech company, Drug development, Financing round, Start-up, France-based company, Healthcare innovation, Biopharmaceuticals, Lyon, Illkirch Graffenstaden, Investment, Life sciences, Inaugural financing, Pharmaceuticals
Funding Rounds & Investors (1)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series A | €2.10M | 2 |
|
17 May 2013 |
ElsaLys Biotech Alternatives & Competitors
ElsaLys Biotech vs
Ablexis, LLC
United States
A superior, next generation transgenic platform.
Series A
1 employees
Biotechnology, Health Care
ElsaLys Biotech vs
ImmunAbs Inc. is Specialized Antibody Pharmaceutical Development Biotech Venture. "Hope for Patient...
Series B
11 employees
Biotechnology, Health Care
ElsaLys Biotech vs
KALSIOM SAS
France
Targeting calcium signaling to cure auto-immune diseases
5 employees
Biotechnology, Health Care
Also compare with:
vs
EnPlusOne Biosciences
vs
EnPlusOne Biosciences
FAQ About ElsaLys Biotech
A frontrunner in therapeutic monoclonal antibody development secures €2.1m in its inaugural financing round.
ElsaLys Biotech was founded in 2013.
ElsaLys Biotech operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Therapeutic monoclonal antibodies, Biotech company, Drug development and Financing round.
ElsaLys Biotech has completed 1 funding round, raising a total of $2.10M. The latest funding stage is Series A.
Top alternatives and competitors to ElsaLys Biotech include Ablexis, LLC, ImmunAbs Inc., KALSIOM SAS, Tridek-One, ILYA Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ElsaLys Biotech and Ablexis, LLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for ElsaLys Biotech, https://bouncewatch.com/company/elsalys-biotech, updated 26 December 2024. When citing, please name BounceWatch and link this page.
